Summary
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/ m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nerenstone SR, Ihde DC, Friedman MA: Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 15(1):1–31, 1988
Davis H, Ramirez G, Ansfield F: Adenocarcinomas of the stomach, pancreas, liver and biliary tract survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193, 1994
Sciarrino E, Simonetti R, Moli S, Pagliaro L: Adriamycin treatment for hepatocellular carcinoma. Cancer 56:2751–2755, 1985
Falkson G, Moertel CG, Lavin P, Pretorius FJ, Meds M, Carbone PP: Chemotherapy studies in primary liver cancer. Cancer 42:2149–2156, 1978
Glover A, Chun HG, Kleinman LM, Cooney DA, Plowman J, Grieshaber CK, Malspeis L, Leyland-Jones B: Merbarone: an antitumor agent entering clinical trials. Inv N Drugs 5:137–143, 1987
Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK:In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49:2578–2583, 1989
DiMaggio JJ, Warrel RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Hanes I, Walsh TD, Baltzer L, Yaldaei S, Young CW: Phase I clinical and pharmacological study of merbarone. Cancer Research 50:1151–1155, 1990
Kraut EH, Grever MR, Staubus AE, Malspeis: Phase I clinical trial of merbarone NSC336628. ASCO abstract A760, 1988
Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone and piroxantrone in Stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. JNCI 85:388–394, 1993
Kraut EH, Fleming T, Macdonald JS, Spiridonidis CH, Bradof JE, Baker LH: Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study. Am J Clin Oncol 16:327–328, 1993
Look KY, Blessing JA, Williams L, Morris M: A phase II trial of merbarone (NSC336628) as salvage therapy for squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. ASCO abstract A839, 1993
Kraut EH, Bendetti J, Balcerzk SP, Doroshow JH: Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study. Inv N Drugs 10:347–349, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poplin, E.A., Tangen, C.M., Harvey, W.H. et al. Hepatoma/merbarone. Invest New Drugs 12, 337–340 (1994). https://doi.org/10.1007/BF00873051
Issue Date:
DOI: https://doi.org/10.1007/BF00873051